OTC Laxative Recalled Due to Microbial Contamination
At this time, there have been no reports of adverse events related to this recall.
Gastroenterology
Skyrizi Approved for Moderately to Severely Active Crohn Disease
The approval was based on data from two phase 3 induction studies, and one phase 3 maintenance study.
Vutrisiran to Undergo FDA Review for Polyneuropathy of Hereditary ATTR Amyloidosis
Vutrisiran is an investigational, subcutaneously-administered RNAi therapeutic designed to block the production of wild-type and mutant transthyretin protein.
FODMAP and Low-Carbohydrate Diets Better Than Meds for IBS
Researchers compared low-carbohydrate and low-FODMAP diets to medication in the treatment of IBS
FDA Approves OTC Omeprazole in Mini Capsule Form
Perrigo received final approval to manufacture Omeprazole Magnesium Delayed-Release Mini Capsules, 20mg.
Ervogastat/Clesacostat Fast Tracked for Nonalcoholic Steatohepatitis
Ervogastat is a diacylglycerol O-acyltransferase 2 inhibitor and clesacostat is an acetyl-CoA carboxylase inhibitor.
Increased Pancreatic Enzymes Prevalent in COVID-19 and Tied to Poor Outcomes
In this meta-analysis, researchers assessed whether an increase in pancreatic enzymes is associated with an increased risk for severe disease and poor outcomes in patients with COVID-19 infection.
Oral STAT3 Inhibitor Granted Orphan Drug Status for Hepatocellular Carcinoma
Direct inhibition of STAT3 signaling by TTI-101 is expected to lead to reduced tumor growth.
Low-FODMAP Diet and CBT for IBS: Efficacy Data and Individualizing Treatment
Authors describe efficacy data on the low-FODMAP-diet and CBT for IBS and factors to consider when personalizing treatment.
Futibatinib Gets Priority Review for Locally Advanced or Metastatic Cholangiocarcinoma
The NDA submission is supported by data from the phase 2b trial evaluating futibatinib in adults with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements.
- Loading...
Loading...
Next post in News
Loading... 
Loading...